Intercept Pharmaceuticals, Inc. (ICPT)

Check out top investors' recommendation for ICPT
Last closing price (N/A)
(0.00%) ? 
Last closing price is the stock price upon last market close (date specified in parenthesis).
Return to date (1m/3m/6m/12m):
N/A ? 
Return to date is the stock return for the specified period of time.
Consensus price target (1m/3m/6m/12m):
125.00
 ? 
Consensus price target is the average analyst price target for a specified period of time.
Buy/Sell Mix (1m/3m/6m/12m):
100%/0%
 ? 
Buy/sell mix the percentage mix between Buy and Sell recommendations for a given company or a research firm. Hold recommendations are excluded.
Description:
Intercept Pharmaceuticals, Inc., a development stage biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat chronic liver diseases utilizing proprietary bile acid chemistry. It primarily develops obeticholic acid, a bile acid analog and farnesoid X receptor (FXR) agonist that is in Phase III clinical trials for the treatment of primary biliary cirrhosis; in Phase IIa clinical trials to treat portal hypertension; in Phase IIb clinical trials for the nonalcoholic steatohepatitis treatment; and in Phase IIa trials for the treatment of bile acid diarrhea. The company is also developing INT-767, an orally administered FXR and TGR5 agonist, which is in preclinical studies to treat fibrosis; and INT-777, an orally administered TGR5 agonist that has completed preclinical studies for the treatment of type 2 diabetes. It has strategic collaborations and research agreements with Dainippon Sumitomo Pharma Co. Ltd. and TES Pharma Srl. The company was founded in 2002 and is headquartered in New York, New York. Intercept Pharmaceuticals, Inc. is a subsidiary of Genextra S.p.A.
Sector:
Analyst
An analyst is a professional research analyst or an Investor Wand user who issued a recommendation for a given company.
Research Firm
A Research Firm is a company that researches and rates stocks and publishes recommendations.
Signal
Signal is a recommendation issued by an analyst. Investor Wand considers two types of recommendations: BUY and SELL.
Signal Date
A signal date is a date when a BUY or SELL recommendation was issued for given security.
Initial Price
Initial Price is the first closing price for a specified company upon recommendation release. If the recommendation is issued in after-market hours, the Initial Price is the next day’s closing price (for a given symbol). In case of dividend distributions and stock splits, Initial Price is adjusted.
Price Target
A Price Target is an analyst’s projection of a company’s stock price by the end of the recommendation period. It represents the price at which the analyst would exit his or her existing position.
Closing Date
Closing Date is the expiration date of a recommendation. The validity timeframe of a professional analyst’s recommendation is 12 months. Investor Wand analysts can set their recommendation timeframe to one, three, six, or 12 months.
Return
The return on a single open recommendation is calculated as the maximum of the current return (based on the latest closing price) and the target price return, if the symbol reached the target. The return on a single closed recommendation is calculated as the maximum of the return on the closing date (at the end of recommendation timeframe) and the target price return, if the stock hit the target price. The return is adjusted for one-time events (e.g., stock splits).
Michael Yee RBC Capital Markets Buy   Oct 18, '19     125.00  Oct 18, '20  N/A 
Alethia Young Deutsche Bank Securities Buy   Mar 11, '19     191.00  Mar 11, '20  N/A 
Liana Moussatos Wedbush Securities Inc. Buy   Mar 08, '19     251.00  Mar 08, '20  N/A 
Brian Abrahams Wells Fargo Securities, Llc Buy   Mar 01, '19     130.00  Mar 01, '20  N/A 
Brian Skorney Brean Murray, Carret & Co. Buy   Feb 19, '19     253.00  Feb 19, '20  N/A 
Ritu Baral Canaccord Genuity Buy   Feb 19, '19     149.00  Feb 19, '20  N/A 
Liana Moussatos Wedbush Securities Inc. Buy   Feb 05, '19     220.00  Feb 05, '20  N/A 
Alethia Young Deutsche Bank Securities Buy   Feb 03, '19     170.00  Feb 03, '20  N/A 
Liisa Bayko JMP Securities Buy   Jan 30, '19     175.00  Jan 30, '20  N/A 
Michael Yee RBC Capital Markets Buy   Jan 28, '19     150.00  Jan 28, '20  N/A 
Alan Carr Needham & Company Buy   Jan 24, '19     150.00  Jan 24, '20  N/A 
Ritu Baral Canaccord Genuity Buy   Jan 07, '19     120.00  Jan 07, '20  N/A 
Michael Yee RBC Capital Markets Buy   Oct 02, '18     135.00  Oct 02, '19  N/A 
Salveen Richter Canaccord Genuity Buy   Aug 06, '18     157.00  Aug 06, '19  N/A 
Liana Moussatos Wedbush Securities Inc. Buy   Aug 03, '18     203.00  Aug 03, '19  N/A 
Brian Abrahams Wells Fargo Securities, Llc Buy   Aug 02, '18     115.00  Aug 02, '19  N/A 
Ritu Baral Canaccord Genuity Buy   Aug 02, '18     120.00  Aug 02, '19  N/A 
Liana Moussatos Wedbush Securities Inc. Buy   Jun 22, '18     203.00  Jun 22, '19  N/A 
Liana Moussatos Wedbush Securities Inc. Buy   May 18, '18     203.00  May 18, '19  N/A 
Michael Yee RBC Capital Markets Buy   Apr 16, '18     135.00  Apr 16, '19  N/A 
< previous123456